Abstract:Chronic hepatitis C virus (HCV) infection is one of the major causes for development of liver cirrhosis and end-stage liver disease. This article reviews two contrasting models of HCV pathogenesis, discusses the merits of each, and presents a rationale for combining the two models into one. Any successful model of HCV pathogenesis must explain how the characteristic features of cirrhosis and end-stage liver disease arise. These features include the loss of hepatocyte function (low serum albumin and reduced clotting ability); the presence of regenerative nodules; and the deposition of excessive extracellular matrix material, especially collagen (fibrosis), which is associated with the transformation of the liver sinusoids to capillary-like structures leading to portal hypertension. A successful model should explain several observations about the rate of disease progression. HCV is characterized by slow progression of fibrogenesis and, importantly, cirrhosis seems to develop only after a long latency (and only in a subset of patients). Among the prognostic factors of disease progression, the age at infection with the HCV virus and the presence of fibrosis appear to be highly relevant in predicting the development of progressive fibrosis. Traditional models of HCV pathogenesis propose that fibrogenesis is the predominant process. Fibrogenesis is induced by activation of fibrogenic cells, such as stellate cells, which results in excessive collagen deposition. By altering the normal architecture and vasculature, the collagen bands finally lead to cirrhosis and loss of organ function. Activation of stellate cells is induced by inflammation, cytokine signaling, and possibly by hepatocyte apoptosis. The telomere model of HCV pathogenesis suggests that hepatocyte damage plays an essential role in the development of cirrhosis. According to this model, hepatocyte damage leads to increased cell turnover, and to the accelerated shortening of hepatocyte telomeres. Critical telomere shortening leads to hepatocyte senescence, loss of hepatocyte function, exhaustion of hepatocellular regeneration, and to a greatly enhanced fibrotic response to injury. This review summarizes both models and presents evidence that these models are not mutually exclusive but rather can be merged into a comprehensive pathogenesis model that outlines the pathway of HCV-induced cirrhosis.

Hepatic Cirrhosis Model of Animal

Research status of animal models about cirrhotic portal hypertension and its complications

Animal Models of Chronic Liver Diseases.

Animal Models Of Chronic Liver Diseases

Multiple Pathogenic Factor-Induced Complications of Cirrhosis in Rats: A New Model of Hepatopulmonary Syndrome with Intestinal Endotoxemia

Pathomorphological changes in the organs of laboratory animals with experimental liver cirrhosis

Establishment of small animal models for portal hypertension and its research progress

Animal and Organoid Models of Liver Fibrosis

Progress in research on animal models of liver cancer

Research progress in animal models of cholangiocarcinoma

An in Vitro Model for Long-Term Hepatotoxicity Testing Utilizing Rat Hepatocytes Entrapped in Micro-Hollow Fiber Reactor

Research progress on rodent models and its mechanisms of liver injury

STUDY ON THE METHOD OF INDUCING CIRROHSIS MODEL IN RATS

A rat model of cirrhosis with well-differentiated hepatocellular carcinoma induced by thioacetamide

Experimental Models of Hepatocellular Carcinoma: Developments and Evolution.

Hepatocellular carcinoma: insight from animal models

Establishment of a New Primary Hepatocellular Carcinoma Model and Its Expression of Some Kinds of Associated Genes

Advances in experimental animal models of hepatocellular carcinoma

Development and Validation of a Primate Model for Liver Fibrosis.

Merging Models of Hepatitis C Virus Pathogenesis

[Current status and perspective of hepatitis C virus models].